Affimed Announced at ASH Meeting, Combination Of Acimtamig With AlloNK Demonstrated An Overall Response Rate Of 86%
Affimed Announced at ASH Meeting, Combination Of Acimtamig With AlloNK Demonstrated An Overall Response Rate Of 86%
Affimed Announced at ASH Meeting, Combination Of Acimtamig With AlloNK Demonstrated An Overall Response Rate Of 86%; Complete Response Of 55% In 22 Heavily Pretreated Patients With Relapsed/Refractory Classical Hodgkin Lymphoma Who Have Exhausted All Standard Of Care Treatments
Affimed在ASH會議上宣佈，Acimtamig與AlloNk聯合治療在22名重度預處理的復發/難治性經典霍奇金淋巴瘤患者中，整體反應率爲86%；完全反應率爲55%，這些患者已用盡所有標準治療。
Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the presentation of data in a poster session at the 66th ASH Annual Meeting and Exposition. The dataset includes 22 patients from the run-in phase of the LuminICE-203 (AFM13-203) phase 2 open-label, multicenter, multi-cohort study. The trial evaluates the safety and efficacy of the combination of acimtamig (AFM13) with Artiva Biotherapeutics' allogeneic NK cell AlloNK in patients with R/R cHL.
Affimed N.V.（納斯達克：AFMD）是一家臨床階段的免疫腫瘤學公司，致力於讓患者恢復與生俱來的抗癌能力。今天在第66屆ASH年度會議和博覽會上宣佈了一組數據的海報展示。該數據集包括來自LuminICE-203（AFM13-203）第二階段開放標籤、多中心、多隊列研究的28名患者的運行階段。這項試驗評估了Acimtamig（AFM13）與Artiva生物治療的異基因Nk細胞AlloNk聯合治療在復發/難治性經典霍奇金淋巴瘤患者中的安全性和有效性。
Acimtamig in combination with AlloNK demonstrated a high overall response rate (ORR) of 86% with complete response (CR) of 55%. All patients in the study were heavily pretreated with a median of 5 (range: 2-13) prior therapies. All patients had received intensive combination chemotherapy, PD(L)1 checkpoint inhibitors and brentuximab vedotin. In addition, about two third of the patients had also received a previous stem cell transplant. The combination regimen exhibited a well-managed safety profile with no unexpected safety signals. Importantly, no cases of graft-versus-host disease (GvHD) or immune effector cell-associated neurotoxicity syndrome (ICANS) were reported.
Acimtamig與AlloNk聯合顯示出86%的高整體反應率（ORR）和55%的完全反應（CR）。研究中的所有患者均爲重度預處理，之前治療的中位數爲5（區間：2-13）。所有患者均接受了強度結合化療、PD（L）1檢查點抑制劑和布倫圖單抗。此外，約三分之二的患者還接受過以前的幹細胞移植。聯合治療方案表現出良好的安全性管理，沒有意外的安全信號。重要的是，未報告任何移植物抗宿主病（GvHD）或免疫效應細胞相關神經毒性綜合徵（ICANS）病例。